|
Showing 1 - 2 of
2 matches in All Departments
Influenza continues to be an ongoing problem despite the existence
of vaccines and drugs. Disease outbreaks can occur relatively
quickly as witnessed with the recent emergence of the influenza
virus A/H1N1 pandemic. The development of new anti-influenza drugs
is thus a major challenge. This volume describes all aspects of the
virus structure and function relevant to infection. The focus is on
drug discovery of inhibitors to the enzyme sialidase, which plays a
key role in the infectious lifecycle of the virus. Following an
overview of the influenza virus, the haemagglutinin, the
interactions with the cell receptors and the enzymology of virus
sialidase, recent results in drug design are presented. These
include a full coverage of the design, synthesis and evaluation of
carbohydrate as well as non-carbohydrate influenza virus sialidase
inhibitors. Further reviews of the clinical experience with
influenza virus sialidase inhibitors and of the development of
resistance to these inhibitor drugs complement the topic.
Influenza continues to be an ongoing problem despite the existence
of vaccines and drugs. Disease outbreaks can occur relatively
quickly as witnessed with the recent emergence of the influenza
virus A/H1N1 pandemic. The development of new anti-influenza drugs
is thus a major challenge. This volume describes all aspects of the
virus structure and function relevant to infection. The focus is on
drug discovery of inhibitors to the enzyme sialidase, which plays a
key role in the infectious lifecycle of the virus. Following an
overview of the influenza virus, the haemagglutinin, the
interactions with the cell receptors and the enzymology of virus
sialidase, recent results in drug design are presented. These
include a full coverage of the design, synthesis and evaluation of
carbohydrate as well as non-carbohydrate influenza virus sialidase
inhibitors. Further reviews of the clinical experience with
influenza virus sialidase inhibitors and of the development of
resistance to these inhibitor drugs complement the topic.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.